Maybe you’ve been on Ozempic® for type 2 diabetes, saw some early weight loss, and then hit a plateau despite exercising. Or maybe the side effects are wearing on you, or your goals shifted. Either way, if you’re thinking about switching to a medication like Zepbound®, here’s what matters: Diabetes and weight loss medications aren’t directly interchangeable, and any switch should happen under your doctor’s guidance.

If you’re considering switching from Ozempic® to Zepbound®, read on to learn what to expect and how to navigate it with the help of your doctor.

‍

Is Zepbound® the same as Ozempic®?

Not quite, though they’re similar. Both Ozempic® (semaglutide) and Zepbound® (tirzepatide) belong to a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). These drugs mimic a hormone that your body produces naturally called glucagon-like peptide-1 (GLP-1).

GLP-1 plays several key roles in the body, including:

• Satiety: Binds to receptors in your brain’s appetite control center (hypothalamus), helping lower the activity of neurons that make you feel hungry while also activating pathways that prolong feelings of fullness
• Insulin secretion: Prompts your pancreas to release insulin only when blood sugar is high after a meal, helping reduce the risk of excessively high or low blood sugar which can cause dizziness or organ damage
• Gastric emptying: Slows the rate at which food leaves the stomach, limiting post-meal blood sugar spikes and prolonging feelings of fullness
• Glucagon suppression: Limits the release of a hormone (glucagon) that tells the liver to release stored blood sugar between meals and after exercise, keeping your post-meal blood sugar stable

What GIP adds

Ozempic® only mimics GLP-1. But Zepbound® replicates a second hormone called glucose-dependent insulinotropic polypeptide (GIP). GIP may enhance GLP-1’s effects by amplifying its insulin response in the pancreas and boosting appetite suppression. GIP also has powerful receptors in fat (white adipose) tissue. When combined with GLP-1, the dual-agonist signal tells under-the-skin (subcutaneous) fat tissue to expand its storage capacity. This locks away free-floating fats inside proper fat cells rather than letting them overflow into the blood or pool around the organs. When too much fat pools around the organs, it can cause chronic inflammation and cardiovascular disease. 

FDA approval

Another difference between these drugs is their approved use: 

• Zepbound® is indicated for weight management in adults with obesity or overweight and a weight-related condition like obstructive sleep apnea or hypertension. This medicine should be paired with a lower-calorie diet and increased exercise. 
• Ozempic® is approved to treat type 2 diabetes and reduce the risk of major cardiovascular events. It’s not a weight-loss medication, though doctors may prescribe it off-label for this use.

A quick comparison

Here’s a simple comparison of Ozempic® versus Zepbound®:

*Doctors may prescribe Ozempic® or Zepbound® off-label (outside their approved indications) for additional purposes. 

2 possible reasons for switching from Ozempic® to Zepbound®

There are two main reasons patients tend to switch from Ozempic® to Zepbound®: efficacy and tolerability. 

1. Efficacy

Doctors may prescribe Ozempic® off-label for weight management, especially in individuals who also have type 2 diabetes. However, if the medication fails to meet weight loss goals, doctors may consider switching to a medication approved for weight loss like the higher-dose formulation of semaglutide (Wegovy®) or Zepbound®. 

Highlighting this comparison, the 2025 SURMOUNT-5 study evaluated 751 adults with a BMI of greater than 30 or a BMI of greater than 27 and at least one weight-related condition like high blood pressure. The key average weight loss outcomes were:

• Tirzepatide (Zepbound®): Participants lost 20.2% of their starting body weight, on average. 
• Semaglutide (Wegovy®): Participants lost 13.7% of their starting body weight, on average. 

Note that the SURMOUNT-5 tested semaglutide at Wegovy®’s maximum FDA-approved weight loss dose (2.4 mg), which exceeds Ozempic®’s maximum diabetes dose (2 mg).

2. Tolerability

Individual responses to GLP-1 RA side effects vary. If you experience stronger side effects on Ozempic®, your doctor may consider switching you to Zepbound®. Offering insight into how these medications compare, the 2021 SURPASS-2 trial followed 1,879 adults with type 2 diabetes for 40 weeks to track treatment discontinuation rates and specific side effects.

Here’s how many discontinued treatment at different doses, plus side effect incidence:

Is switching from Ozempic® to Zepbound® safe?

Switching from Ozempic® to Zepbound® is generally considered safe. However, before prescribing, your doctor will screen for contraindications, precautions, and drug interactions.

Contraindications

Contraindications are conditions or circumstances that make a medication unsafe for you. Both Ozempic® and Zepbound® are contraindicated for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). This is due to rodent studies that showed these drugs may cause thyroid C-cell tumors. Studies haven’t observed these tumors in humans, but the black box warning exists as a precaution. These drugs are also contraindicated for individuals with a history of allergic reaction to semaglutide, tirzepatide, or any inactive ingredients in the formulations.

Warnings and precautions

Ozempic® and Zepbound® carry additional warnings and precautions that don’t qualify as contraindications. These existing conditions warrant screening and monitoring but don’t prohibit you taking the medication:

• Pancreatitis: Acute inflammation of the pancreas
• Gallbladder disease: Gallstones or inflammation and swelling (cholecystitis)
• Kidney health: Fluid loss and acute kidney injury caused by severe gastrointestinal side effects like diarrhea and vomiting

Drug interactions

Many medications that interact with Ozempic® also interact with Zepbound®. But the crossover isn’t one-to-one. Because both drugs slow down gastric emptying, they can delay or reduce the absorption of oral medications taken at the same time. For Zepbound® specifically, doctors advise patients to switch to a non-oral birth control or add a barrier method during initiation and dose escalations. Your doctor should discuss all possible drug interactions with you before prescribing. 

‍

How to switch safely from Ozempic® to Zepbound®

If switching makes sense, your doctor will guide the transition. But keep in mind: There’s no set Ozempic®-to-Zepbound® conversion chart. Everyone’s transition looks a little different. 

Your doctor may recommend tapering you off Ozempic®, or they might advise discontinuing the drug outright. In either case, a gap before starting Zepbound® (washout period) may be involved. When appropriate, your doctor will guide you through titration, which means starting on a low dose of a medication and gradually increasing it over time. This is to help your body adjust to the new regimen. You’ll take periodic steps up to the dose you’ll remain on (maintenance dose).

Switching from Ozempic® to Zepbound®: Dosage

The standard Zepbound titration process looks like this:

• Month one: 2.5 mg once weekly
• Month two: 5 mg once weekly
• Each month onward: Periodic steps of 2.5 mg up to your maintenance dose (maximum 15 mg), with at least four weeks between steps

‍

Side effects after switching Ozempic® to Zepbound®

You may experience side effects when starting Zepbound® or following dose increases. Gastrointestinal (GI) side effects are the most common, including:

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain

There are other potential side effects, too. These include injection-site reactions and fatigue. Most side effects are mild to moderate in severity. If yours are severe or persistent, talk to your doctor to understand your next steps.

‍

Cost and insurance changes

Insurance coverage is often a key consideration in the choice to switch medications. Plans often cover Ozempic’s® FDA-approved diabetes indication while denying coverage for weight loss drugs like Zepbound®.

Maven Clinic can help you navigate these insurance hurdles. For members without coverage, Maven offers transparent self-pay options for starting doses: 

• Zepbound® KwikPen®: $299 per month
• Zepbound® Vial: $299 per month
• Zepbound® Pen: $1,000-plus per month

With active insurance coverage, out-of-pocket costs can drop as low as $25 per month. Contact your insurance to verify individual coverage and costs.

‍

Navigate the switch from Ozempic® to Zepbound® with Maven Clinic

Switching from Ozempic® to Zepbound® is a decision you should only make under a doctor’s supervision. Our specialists at Maven Clinic can help you navigate your options and discover which medication works best for your individual needs and goals. We take a whole-person approach to weight loss care. As our patient, Diane, expressed: "My clinician covered things I hadn't thought to ask, like how GLP-1s can affect birth control. I felt like I was making an informed decision instead of just following a trend."

If you’re considering switching from Ozempic® to Zepbound®, connect with Maven Clinic’s GLP-1 care team to explore your options.